Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB1000
- Development stage
- Preclinical
- Lead developer
- Alveolus Bio
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
AB1000 is an inhaled live biotherapeutic product (LBP) developed by Alveolus Biomedical for the treatment of chronic and acute respiratory diseases. As a microbial-based therapy, it is designed to be delivered directly to the respiratory tract via inhalation to restore or modulate the lung microbiome, thereby addressing local inflammation and tissue damage. The program is currently in the IND-enabling phase for Chronic Obstructive Pulmonary Disease (COPD) and is undergoing preclinical evaluation for other indications, including bronchopulmonary dysplasia, pulmonary fibrosis, and lung injury resulting from viral infections.
Beyond the preview
Go deeper on AB1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB1000.